Abstract Number: 956 • 2016 ACR/ARHP Annual Meeting
The Effect of Treatment Adjustments Aimed at DAS Remission on Physical Functioning in Undifferentiated and Rheumatoid Arthritis Patients in Low Disease Activity
Background/Purpose: Should we aim at remission if patients are in low disease activity (LDA)? We assessed if rheumatoid or undifferentiated arthritis (RA, UA) patients who…Abstract Number: 2536 • 2016 ACR/ARHP Annual Meeting
The Performance of a Single Centre Interventional Clinic in Early Rheumatoid Arthritis
Background/Purpose: In early rheumatoid arthritis (RA), first assessment by a rheumatologist and/or initiation of disease-modifying anti-rheumatic drugs (DMARD) within 12 weeks of symptom onset are…Abstract Number: 556 • 2015 ACR/ARHP Annual Meeting
Induction-Maintenance in Early RA: A Meta-Analysis of Trials Using MTX Plus Adalimumab As Induction Therapy
Background/Purpose: The goal of rheumatoid arthritis (RA) treatment is remission or, when not achievable, low-disease-activity (LDA). Initial combined therapy with MTX + anti-TNF achieves these…Abstract Number: 1948 • 2015 ACR/ARHP Annual Meeting
Early Rheumatoid Arthritis Patients Have Higher Fractions of Circulating Th2 Cells, Th17 Cells and Regulatory T Cells, Similar Fractions of Follicular Helper T Cells, and Lower Fractions of Th17/Th1 Cells and Th1 Cells Compared to Healthy Controls
Background/Purpose: A comprehensive analysis of the circulating T cell subtype pattern, including T helper 1 (Th1) cells, Th2 cells, Th17 cells, Th1/Th17 cells, T follicular…Abstract Number: 3256 • 2015 ACR/ARHP Annual Meeting
Epigenetic Chromosome Conformations Predict MTX Responsiveness in Early Rheumatoid Arthritis Patients
Background/Purpose: In early rheumatoid arthritis (RA), it is not possible to predict response to first line DMARDs (e.g. methotrexate (MTX)) and as such treatment decisions…Abstract Number: 50 • 2015 ACR/ARHP Annual Meeting
Characteristics and Outcomes Associated with Early Corticosteroid Use in a Large Multicenter Canadian RA Cohort
Background/Purpose: Synthetic glucocorticoids (steroids) are commonly used in RA to rapidly inhibit pro-inflammatory cytokines. They are frequently used as "bridge therapy", quickly dampening down the…Abstract Number: 557 • 2015 ACR/ARHP Annual Meeting
Early Intensification of Treatment Induces Superior Outcomes in Two Randomized Trials According to Predicted Vs. Observed Radiographic Progression in Rheumatoid Arthritis
Background/Purpose: Predicted vs. Observed Radiographic Progression in early Rheumatoid Arthritis (POPeRA) is a method that has previously confirmed the relative radiographic efficacy of synthetic disease-modifying…Abstract Number: 2129 • 2015 ACR/ARHP Annual Meeting
Treatment-Naïve, Early Rheumatoid Arthritis Patients Demonstrate Abnormalities of Vascular and Myocardial Function on Cardiac MRI
Treatment-na•ve, early rheumatoid arthritis patients demonstrate abnormalities of vascular and myocardial function on cardiac MRIB Erhayiem, A McDiarmid, PP Swoboda, A Kidambi, DP Ripley, TA…Abstract Number: 434 • 2015 ACR/ARHP Annual Meeting
Duration of Remission By Currently Available Criteria Can Predict Physical Functioning, but Not Radiological Progression in Early Rheumatoid Arthritis Patients
Background/Purpose: Several sets of remission criteria have been developed. The ACR/EULAR criteria were validated against their potential to predict prognosis of rheumatoid arthritis (RA) [1].…Abstract Number: 568 • 2015 ACR/ARHP Annual Meeting
Superiority of Initial Combination- over Step up Therapy in Treatment to the Target of Remission in Daily Clinical Practice in Early Rheumatoid Arthritis Patients: Results from the DREAM Registry
Background/Purpose: Treat-to-target (T2T) of remission strategies has been widely accepted as the standard of care for patients with Rheumatoid Arthritis (RA). In early RA, implementation…Abstract Number: 2595 • 2015 ACR/ARHP Annual Meeting
Autoantibodies to Citrullinated Fibrinogen, Anti-CCP2 and Anti-MCV Antibodies in Early Rheumatoid Arthritis Patients with Rapid Radiographic Progression at 1-Year
Background/Purpose: We compared the ability of anti-CCP2, anti-mutated citrullinated vimentin (anti-MCV) and anti-citrullinated fibrinogen (AhFibA) antibodies to predict 1-year rapid radiographic progression (RRP; total Sharp…Abstract Number: 454 • 2015 ACR/ARHP Annual Meeting
No Sex Bias in the Escalation of Therapy in the Treatment of Early Inflammatory Arthritis
Background/Purpose: Several studies have shown that females with early inflammatory arthritis have higher disease activity, worse functional impairment and worse patient-reported outcomes but do not…Abstract Number: 571 • 2015 ACR/ARHP Annual Meeting
Malignancy Data in Tofacitinib-Treated Japanese Patients with Rheumatoid Arthritis
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). In the global tofacitinib RA clinical program, rates and types…Abstract Number: 2620 • 2015 ACR/ARHP Annual Meeting
Predictive Value of Anti-Carbamylated Protein Antibodies in Patients with Early Arthritis
Background/Purpose: Anti-carbamylated protein (anti-CarP) antibodies have been described as a new type of autoantibodies specific of patients with rheumatoid arthritis (RA). They seem useful as…Abstract Number: 466 • 2015 ACR/ARHP Annual Meeting
Clinical Factors, Anti-Citrullinated Peptide Antibodies and MRI-Detected Subclinical Inflammation in Relation to Progression from Clinically Suspect Arthralgia to Arthritis
Background/Purpose: Patients with Clinically Suspect Arthralgia (CSA) have, according to their rheumatologists, an increased risk on rheumatoid arthritis (RA), but their actual outcome is unexplored.…
- « Previous Page
- 1
- …
- 8
- 9
- 10
- 11
- 12
- …
- 18
- Next Page »